Failing Health: NDIA’s Annual Vital Signs Report Highlights Weaknesses in the Defense Industrial Base Supply Chain
Client Alert | 1 min read | 02.10.22
The National Defense Industrial Association (NDIA) recently published its 2022 Vital Signs: The Health and Readiness of the Defense Industrial Base report, which includes an analysis of the defense industrial base supply chain. The annual report highlights the degree to which the performance of the supply chain is impacted by external events, namely the COVID-19 pandemic, which in turn impacts internal performance metrics. The report posits that the defense industrial base is not inoculated against the same concerns that have negatively impacted commercial supply chains – i.e., the semiconductor shortage. NDIA researchers analyze four supply chain metrics to conclude that the overall performance of defense supply chains has substantively declined from the previous year and is failing: (1) contract failure; (2) financial performance; (3) inventory performance; and (4) cost management. The report also notes that only 30 out of 245 NDIA members surveyed (12%) indicated that their company’s supplier network would be more reliable at delivering goods, materials and services in the future. The remaining 215 members surveyed (88%) concluded that their company’s supplier networks would be about the same or less reliable. In total, the 2022 Vital Signs report paints a bleak picture of the overall health of the defense industrial base supply chain, and NDIA researchers conclude that next year’s supply chain challenges will be even greater.
For more information on managing supply chain risks, please attend Crowell & Moring’s upcoming webinar:
- Thursday, February 24 – White Collar & Regulatory Enforcement Issues in Supply Chain
Contacts
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection


